| 前收市價 | 0.1000 |
| 開市 | 0.1000 |
| 買盤 | 0.0500 |
| 賣出價 | 0.1500 |
| 拍板 | 3.00 |
| 到期日 | 2024-07-19 |
| 今日波幅 | 0.1000 - 0.1200 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 473 |
BenzingaOral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
On Tuesday, Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film. Anaphylm is the company’s first and only orally administered epinephrine prodrug product candidate under development for severe life-threatening allergic reactions, including anaphylaxis. In March, Aquestive Therapeutics released topline clinical data from its Phase 3 PK study of Anaphylm, meeting all prim
Zacks5 Small Drug Stocks to Buy From a Recovering Industry
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Insider MonkeyAquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript May 8, 2024 Aquestive Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Aquestive Therapeutics First Quarter 2024 Conference Call. At this time, all participants […]
